Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer

by | Aug 1, 2021

Top Biopharma Partnership by Upfront Cash and Equity

July 2021

Arvinas development and commercialization deal with Pfizer for ARV-471

Announced: July 22, 2021

Total Deal Value: $2,400M

Upfront Cash: $650M

Upfront Equity: $350M (3.5M new common, 30% prem.)

Option Payments: n/a

Milestones: $1,400M ($400M Reg. and $1B Sales)

Cost and Profit Split: 50%

The Asset:

Phase II ARV-471 oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader for the treatment of estrogen receptor (ER) positive or human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.

Deal Structure:

Development and Commercial License

Partnership Features:

Equal cost and profit split for development and commercialization.

The Details:

  • Arvinas granted Pfizer exclusive, worldwide rights to develop and commercialize ARV-471 for ER+/HER2- breast cancer.
  • Arvinas and Pfizer will split development and commercialization costs and profits equally.
  • Arvinas will receive $650M in upfront cash and Pfizer will receive approximately 3.5M newly issued shares of Arvinas common stock at a 30% premium valued at $350M, which represents an approx. 7% equity ownership stake by Pfizer. Additionally, Arnivas is eligible for up to $400M in approval milestones and up to $1B in commercial milestones.

Last Month:

The Deal of the Month for June 2021 was iTeos and GSK’s TIGIT deal with $625M up front for EOS-448. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.


Deal Profiles


Funding Rounds


Company Profiles


Product Profiles


Clinical Trials


Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.

read more
Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.